+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Liver Fibrosis Drugs Market - Global Forecast 2026-2032- Product Image
Liver Fibrosis Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Liver Fibrosis Drugs Market - Global Forecast 2026-2032

  • Report

  • 183 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4904956
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Liver Fibrosis Drugs Market is projected to reach USD 18.56 Billion in 2026. It is expected to continue growing at a CAGR of 8.68%, reaching USD 30.71 Billion by 2032.

Liver fibrosis drugs are moving from supportive disease management toward targeted intervention across metabolic dysfunction-associated steatohepatitis (MASH), viral hepatitis, alcohol-associated liver disease, cholestatic disorders, and autoimmune liver diseases. Fibrosis is clinically important because progressive scarring can lead to cirrhosis, portal hypertension, liver failure, and hepatocellular carcinoma, making earlier diagnosis and treatment central to specialty care pathways.

The market is being reshaped by the 2024 U.S. approval of resmetirom for noncirrhotic MASH with moderate-to-advanced fibrosis, which created the first approved therapy for this high-burden metabolic liver disease segment. Growth is also supported by noninvasive tests, elastography, biomarker panels, and trial designs that increasingly focus on fibrosis improvement without worsening steatohepatitis.

Transformative Shifts in the Liver Fibrosis Treatment Landscape

The liver fibrosis treatment landscape is shifting from late-stage cirrhosis management to earlier identification of patients with F2-F3 fibrosis. This transition is supported by wider use of transient elastography, MRI-based techniques, serum biomarkers, and risk stratification tools in hepatology, endocrinology, and primary care.

Drug development is also diversifying beyond single-mechanism antifibrotics. Developers are advancing metabolic modulators, thyroid hormone receptor beta agonists, GLP-1-based therapies, FXR agonists, FGF analogs, PPAR agonists, anti-inflammatory agents, and combination strategies. The result is a more competitive liver fibrosis drugs market where clinical differentiation depends on histology, noninvasive endpoints, safety, cardiometabolic benefit, and payer acceptance.

Cumulative Impact of Artificial Intelligence on Liver Fibrosis Drugs

Artificial intelligence is becoming a practical enabler across liver fibrosis drug discovery, clinical development, and patient identification. AI-supported image analysis can standardize histology interpretation, quantify fibrosis patterns, and reduce variability in biopsy assessment, while machine learning models can integrate laboratory values, imaging, genomics, and claims data to identify high-risk patients earlier.

In development programs, AI can improve site selection, trial recruitment, endpoint modeling, and real-world evidence generation. Its cumulative impact is strongest where it connects fragmented clinical data with noninvasive diagnostics, helping manufacturers demonstrate disease modification, optimize adherence programs, and build evidence packages for regulators and payers.

Key Regional Insights for Liver Fibrosis Drugs

North America remains a key commercial and regulatory reference point due to high metabolic disease prevalence, established hepatology networks, advanced diagnostic adoption, and the U.S. launch environment for the first approved MASH-directed therapy. Europe benefits from strong public health systems, guideline-driven care, and active clinical research, although reimbursement scrutiny and health technology assessment requirements can slow access in several countries.

Asia-Pacific is strategically important because of large patient pools, rising obesity and diabetes rates, persistent viral hepatitis burden in several markets, and expanding clinical trial infrastructure in China, India, Japan, South Korea, and Australia. Latin America, led by Brazil and Mexico, shows rising demand as metabolic liver disease recognition increases and specialist referral pathways improve, while the Middle East faces a substantial diabetes and obesity burden that supports screening and specialty care expansion. Africa presents long-term need linked to viral hepatitis, alcohol-related liver disease, and limited access to advanced diagnostics, making affordability, diagnostic reach, and health system capacity decisive for liver fibrosis treatment adoption.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

Across ASEAN, liver fibrosis drug demand is influenced by the dual burden of viral hepatitis and fast-rising metabolic disease, with Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines expanding diagnostic and specialty care capacity at different speeds. GCC markets are shaped by high diabetes and obesity prevalence, strong hospital investment, and government-led specialty care modernization, creating demand for liver fibrosis diagnostics, hepatology services, and evidence-based pharmacologic options.

The European Union offers scale through centralized regulatory pathways, coordinated pharmacovigilance, and sophisticated health technology assessment, while BRICS countries combine large untreated populations with local manufacturing capacity, expanding clinical trial participation, and increasing public health focus on hepatitis and metabolic liver disease. G7 markets remain the benchmark for premium drug launches, evidence standards, and payer negotiation. NATO countries overlap heavily with North American and European systems, where supply security, data governance, and resilient pharmaceutical value chains are increasingly important for liver fibrosis drug access and continuity of care.

Key Country Insights for Liver Fibrosis Drug Commercialization

The United States leads in commercial opportunity because of specialty access, high MASH prevalence, broad use of advanced diagnostics, and rapid uptake potential for approved and late-stage therapies. Canada offers structured reimbursement, strong academic hepatology centers, and organized specialist networks, while Mexico and Brazil represent growing Latin American opportunities as metabolic disease, obesity, diabetes, and specialist referral networks expand.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are central to adoption, with Germany often important for early European market access and France, Italy, Spain, and the United Kingdom emphasizing cost-effectiveness, guideline alignment, and real-world outcomes. Russia remains clinically relevant due to liver disease burden, though market access is affected by geopolitical, reimbursement, and supply constraints.

China and India provide major long-term volume potential due to population scale, diabetes growth, obesity trends, and hepatitis-related fibrosis, while Japan and South Korea offer advanced diagnostics, aging populations, and strong clinical research environments. Australia remains attractive for early diagnosis programs, high-quality trial infrastructure, specialist-driven adoption, and public health attention to metabolic liver disease.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize therapies with clear fibrosis benefit, favorable cardiometabolic profiles, and safety suitable for chronic use. Development plans should integrate noninvasive biomarkers, histology where required, real-world evidence, and patient segmentation by etiology, fibrosis stage, and metabolic risk.

Commercial teams should invest in hepatology-endocrinology referral pathways, payer evidence, diagnostic partnerships, and physician education. Organizations that combine drug efficacy with scalable patient identification, adherence support, and region-specific pricing strategies will be best positioned in the liver fibrosis drugs market.

Research Methodology

This executive summary is based on secondary research from regulatory announcements, clinical trial registries, peer-reviewed hepatology literature, public health agencies, product labels, and recognized medical guidelines. Findings were cross-checked across therapeutic mechanisms, disease etiologies, regulatory milestones, regional care patterns, and market access factors.

The methodology emphasizes verified evidence over speculative sizing. Analysis considers drug class innovation, approved therapy benchmarks, clinical endpoints, noninvasive diagnostics, patient identification barriers, reimbursement dynamics, and regional differences in liver disease burden and health system readiness.

Conclusion

The liver fibrosis drugs market has entered a more actionable phase as approved MASH therapy, stronger diagnostics, and diversified pipelines converge. The opportunity extends beyond a single disease label, spanning metabolic, viral, alcohol-related, cholestatic, and autoimmune causes of fibrosis.

Success will depend on proving durable fibrosis improvement, identifying patients before cirrhosis, and demonstrating value to payers. Industry participants that align clinical innovation with AI-enabled diagnostics, regional access strategies, and real-world evidence will shape the next decade of liver fibrosis treatment.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Liver Fibrosis Drugs Market, by Drug Class
7.1. Introduction
7.2. Biologic Therapies
7.2.1. Monoclonal Antibodies
7.2.2. Recombinant Proteins
7.3. Cell Therapies
7.4. Gene Therapies
7.5. Small Molecule Inhibitors
7.5.1. Natural Products
7.5.2. Synthetic Compounds
8. Liver Fibrosis Drugs Market, by Mechanism Of Action
8.1. Introduction
8.2. ASK1 Inhibitors
8.3. Galectin-3 Inhibitors
8.4. PPAR Agonists
8.4.1. PPAR Alpha
8.4.2. PPAR Delta
8.4.3. PPAR Gamma
8.5. TGF Beta Blockers
9. Liver Fibrosis Drugs Market, by Route Of Administration
9.1. Introduction
9.2. Injectable
9.2.1. Intravenous
9.2.2. Subcutaneous
9.3. Oral
10. Liver Fibrosis Drugs Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
10.4.1. Chain Pharmacy
10.4.2. Independent Pharmacy
11. Liver Fibrosis Drugs Market, by Region
11.1. Asia-Pacific
11.2. Europe
11.3. North America
11.4. Latin America
11.5. Africa
11.6. Middle East
12. Liver Fibrosis Drugs Market, by Group
12.1. NATO
12.2. G7
12.3. European Union
12.4. BRICS
12.5. ASEAN
12.6. GCC
13. Liver Fibrosis Drugs Market, by Country
13.1. United States
13.2. China
13.3. Germany
13.4. Japan
13.5. India
13.6. United Kingdom
13.7. France
13.8. Canada
13.9. Italy
13.10. Australia
13.11. South Korea
13.12. Brazil
13.13. Mexico
13.14. Russia
13.15. Spain
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. FPNV Positioning Matrix, 2025
14.3. Market Concentration Analysis, 2025
14.3.1. Concentration Ratio (CR)
14.3.2. Herfindahl Hirschman Index (HHI)
14.4. Recent Developments & Impact Analysis, 2025
14.5. Product Portfolio Analysis, 2025
14.6. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Akero Therapeutics, Inc.
15.2. Alentis Therapeutics AG
15.3. Alnylam Pharmaceuticals, Inc.
15.4. AstraZeneca PLC
15.5. Boehringer Ingelheim International GmbH
15.6. Bristol-Myers Squibb Company
15.7. Cirius Therapeutics, Inc.
15.8. Eli Lilly and Company
15.9. FibroGen, Inc.
15.10. Galectin Therapeutics, Inc.
15.11. Gilead Sciences, Inc.
15.12. Hepion Pharmaceuticals, Inc.
15.13. Intercept Pharmaceuticals, Inc.
15.14. Inventiva Pharma
15.15. Ionis Pharmaceuticals, Inc.
15.16. Madrigal Pharmaceuticals, Inc.
15.17. Merck & Co., Inc.
15.18. NorthSea Therapeutics B.V.
15.19. Novartis AG
15.20. Novo Nordisk A/S
15.21. Pfizer Inc.
15.22. Pharmaxis Ltd.
15.23. Pliant Therapeutics, Inc.
15.24. Sagimet Biosciences Inc.
15.25. Takeda Pharmaceutical Company Limited
15.26. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL LIVER FIBROSIS DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL LIVER FIBROSIS DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL LIVER FIBROSIS DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL LIVER FIBROSIS DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 13. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 17. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 19. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL LIVER FIBROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 21. GLOBAL LIVER FIBROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL LIVER FIBROSIS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL BIOLOGIC THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL BIOLOGIC THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL BIOLOGIC THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL CELL THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL CELL THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL CELL THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL GENE THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL GENE THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL GENE THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL SMALL MOLECULE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL SMALL MOLECULE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL SMALL MOLECULE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL NATURAL PRODUCTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL NATURAL PRODUCTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL NATURAL PRODUCTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL SYNTHETIC COMPOUNDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL SYNTHETIC COMPOUNDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL SYNTHETIC COMPOUNDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL ASK1 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL ASK1 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL ASK1 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL GALECTIN-3 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL GALECTIN-3 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL GALECTIN-3 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL PPAR AGONISTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL PPAR AGONISTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL PPAR AGONISTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL PPAR ALPHA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL PPAR ALPHA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL PPAR ALPHA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL PPAR DELTA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL PPAR DELTA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL PPAR DELTA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL PPAR GAMMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL PPAR GAMMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL PPAR GAMMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL TGF BETA BLOCKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL TGF BETA BLOCKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL TGF BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL CHAIN PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL CHAIN PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL CHAIN PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL INDEPENDENT PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL INDEPENDENT PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL INDEPENDENT PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 82. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 83. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 84. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 85. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2017-2032 (USD MILLION)
TABLE 86. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 87. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2017-2032 (USD MILLION)
TABLE 90. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 92. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 93. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 94. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 95. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2017-2032 (USD MILLION)
TABLE 96. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 97. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 98. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 99. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2017-2032 (USD MILLION)
TABLE 100. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 102. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 103. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 104. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 105. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2017-2032 (USD MILLION)
TABLE 106. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 107. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 108. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 109. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2017-2032 (USD MILLION)
TABLE 110. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 111. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 112. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 113. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 114. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 115. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2017-2032 (USD MILLION)
TABLE 116. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 117. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 118. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 119. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2017-2032 (USD MILLION)
TABLE 120. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 121. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 122. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 123. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 124. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 125. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2017-2032 (USD MILLION)
TABLE 126. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 127. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 128. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 129. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2017-2032 (USD MILLION)
TABLE 130. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 131. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 132. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 133. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 134. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 135. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2017-2032 (USD MILLION)
TABLE 136. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 137. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 138. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 139. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 141. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 142. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 143. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 144. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 145. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 146. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2017-2032 (USD MILLION)
TABLE 147. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 148. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 149. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 150. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2017-2032 (USD MILLION)
TABLE 151. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 152. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 153. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 154. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 155. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 156. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2017-2032 (USD MILLION)
TABLE 157. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 158. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 159. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 160. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2017-2032 (USD MILLION)
TABLE 161. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 162. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 163. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 164. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 165. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 166. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2017-2032 (USD MILLION)
TABLE 167. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 168. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 169. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 170. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2017-2032 (USD MILLION)
TABLE 171. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 172. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 173. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 174. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 175. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 176. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2017-2032 (USD MILLION)
TABLE 177. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 178. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 179. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 180. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2017-2032 (USD MILLION)
TABLE 181. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 182. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 183. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 184. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 185. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 186. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2017-2032 (USD MILLION)
TABLE 187. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 188. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 189. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 190. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2017-2032 (USD MILLION)
TABLE 191. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 192. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 193. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 194. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 195. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 196. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2017-2032 (USD MILLION)
TABLE 197. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 198. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 199. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 200. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2017-2032 (USD MILLION)
TABLE 201. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 202. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 203. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 204. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 205. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 206. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 207. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2017-2032 (USD MILLION)
TABLE 208. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 209. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 210. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 211. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2017-2032 (USD MILLION)
TABLE 212. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 213. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 214. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 215. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 216. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 217. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2017-2032 (USD MILLION)
TABLE 218. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 219. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 220. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 221. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2017-2032 (USD MILLION)
TABLE 222. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 223. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 224. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 225. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 226. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 227. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2017-2032 (USD MILLION)
TABLE 228. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 229. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 230. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 231. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2017-2032 (USD MILLION)
TABLE 232. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 233. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 234. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 235. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 236. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 237. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2017-2032 (USD MILLION)
TABLE 238. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 239. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 240. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 241. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2017-2032 (USD MILLION)
TABLE 242. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 243. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 244. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 245. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 246. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 247. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2017-2032 (USD MILLION)
TABLE 248. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 249. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 250. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 251. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2017-2032 (USD MILLION)
TABLE 252. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 253. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 254. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 255. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 256. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 257. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2017-2032 (USD MILLION)
TABLE 258. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 259. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 260. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 261. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2017-2032 (USD MILLION)
TABLE 262. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 263. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 264. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 265. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 266. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 267. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2017-2032 (USD MILLION)
TABLE 268. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 269. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 270. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 271. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2017-2032 (USD MILLION)
TABLE 272. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 273. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 274. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 275. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 276. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 277. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2017-2032 (USD MILLION)
TABLE 278. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 279. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 280. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 281. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2017-2032 (USD MILLION)
TABLE 282. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 283. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 284. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 285. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 286. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 287. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2017-2032 (USD MILLION)
TABLE 288. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 289. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 290. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 291. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2017-2032 (USD MILLION)
TABLE 292. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 293. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 294. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 295. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 296. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 297. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2017-2032 (USD MILLION)
TABLE 298. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 299. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 300. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 301. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2017-2032 (USD MILLION)
TABLE 302. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 303. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 304. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 305. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 306. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 307. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2017-2032 (USD MILLION)
TABLE 308. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 309. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 310. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 311. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2017-2032 (USD MILLION)
TABLE 312. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 313. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 314. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 315. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 316. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 317. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2017-2032 (USD MILLION)
TABLE 318. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 319. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 320. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 321. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2017-2032 (USD MILLION)
TABLE 322. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 323. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 324. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 325. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 326. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 327. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2017-2032 (USD MILLION)
TABLE 328. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 329. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 330. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 331. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2017-2032 (USD MILLION)
TABLE 332. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 333. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 334. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 335. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 336. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 337. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2017-2032 (USD MILLION)
TABLE 338. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 339. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 340. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 341. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2017-2032 (USD MILLION)
TABLE 342. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 343. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 344. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 345. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 346. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 347. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2017-2032 (USD MILLION)
TABLE 348. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 349. SPAIN LIVER FIBROSIS DRUGS MARKET S

Companies Mentioned

  • Akero Therapeutics, Inc.
  • Alentis Therapeutics AG
  • Alnylam Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cirius Therapeutics, Inc.
  • Eli Lilly and Company
  • FibroGen, Inc.
  • Galectin Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • Hepion Pharmaceuticals, Inc.
  • Intercept Pharmaceuticals, Inc.
  • Inventiva Pharma
  • Ionis Pharmaceuticals, Inc.
  • Madrigal Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • NorthSea Therapeutics B.V.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Pharmaxis Ltd.
  • Pliant Therapeutics, Inc.
  • Sagimet Biosciences Inc.
  • Takeda Pharmaceutical Company Limited
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages183
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 18.56 Billion
Forecasted Market Value ( USD ) by 2032 $ 30.71 Billion
Compound Annual Growth Rate8.6%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Liver Diseases Therapeutics Market - Global Forecast 2026-2032 - Product Image

Liver Diseases Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From
Liver Fibrosis Drug Pipeline Analysis Report 2026 - Product Image

Liver Fibrosis Drug Pipeline Analysis Report 2026

  • Drug Pipelines
  • 150 Pages
  • Global
From
Non-alcoholic Steatohepatitis (NASH) Drug Market Analysis: Explosive Growth, Breakthroughs, and Competitive Dynamics (2026-2031) - Product Image

Non-alcoholic Steatohepatitis (NASH) Drug Market Analysis: Explosive Growth, Breakthroughs, and Competitive Dynamics (2026-2031)

  • Report
  • 124 Pages
  • Global
From
Liver Diseases Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Liver Diseases Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 125 Pages
  • Global
From
Primary Sclerosing Cholangitis (PSC) Drug Market: Industry Dynamics, Pipeline Innovations, and Strategic Outlook - Product Image

Primary Sclerosing Cholangitis (PSC) Drug Market: Industry Dynamics, Pipeline Innovations, and Strategic Outlook

  • Report
  • 148 Pages
  • Global
From

About the Liver Fibrosis Drug Market

The Liver Fibrosis Drug market is a subset of the pharmaceutical industry focused on the development of treatments for liver fibrosis. Clinical trials are a key component of the development process, as they provide evidence of the safety and efficacy of a drug. Clinical trials are conducted in phases, with each phase providing increasingly detailed information about the drug's effects. The first phase of a clinical trial typically involves a small number of participants and is designed to assess the safety of the drug. Subsequent phases involve larger numbers of participants and are designed to assess the efficacy of the drug. The Liver Fibrosis Drug market is highly competitive, with many companies vying for a share of the market. Companies in the market include Gilead Sciences, Merck, Novartis, Pfizer, and Roche. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.